Cannvas MedTech (CSE:MTEC), a leading business technology company in the cannabis space, is pleased to introduce its second cannabis-centric educational platform, aimed at healthcare and wellness through cannabis for furry family friends. Built on the same infrastructure as Cannvas.Me, Cannvas.PET will be a scalable and comprehensive solution for the global pet community offering interactive tools and research-backed content to audiences who wish to learn about pet healthcare through cannabis.

“As pet owners search for natural alternatives to improve the health of their pet, more and more are looking to medical cannabis only to find a lack of quality information,” said Steve Loutskou, Chief Operating Officer, Global Markets, Cannvas MedTech Inc. “We are leveraging our existing infrastructure to launch an online educational portal targeted at the large and growing market for cannabis pet products. Cannvas.PET will be a leading source of alternative healthcare for all manner of pets, providing owners with information and education regarding the various treatments available. While supporting a healthy and happy lifestyle for pets, it will stand independent from licensed producers and other entities to ensure unbiased information is free from outside influences.”


Similar to the Cannvas.Me education platform, Cannvas.PET will be a free-to-use online platform using machine-learning algorithms and artificial intelligence to contextualize and adapt to users of the platform, ensuring the content they are served remains geographically and personally relevant to them. The site will feature innovative tools such as educational learning modules and an interactive service to educate pet owners with specific concerns about the different strains available.

With the legalization of cannabis on October 17, 2018 Canadian pet owners will have the opportunity to use medical-grade cannabis for the health care of their pets. Similar to the human medical cannabis marketplace, high-quality non-combustible cannabis products can be a natural alternative in supporting the overall health and well-being of pets. Pets suffer just like humans and with the growing demand for alternative treatments there is a need for a trusted source of medical cannabis treatments to help with pet-related ailments. Research on CBD treats and oils has shown promise in many pet ailments like phobias, digestive problems inflammation and pain.

In Canada, there are approximately 16 million cats and dogs with almost two-thirds of households owning a pet. Pet owners are increasingly treating pets as an extension of their family, driving annual pet-related expenditures to in excess of $5 billion in Canada and almost US$70 billion in the United States.

With over 350 million pets globally, there is a sizeable market opportunity for cannabis products and supporting technologies like the scalable Cannvas.PET educational platform.

About Cannvas MedTech Inc.

Cannvas MedTech is a leading business technology company in the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted onwww.sedar.com.

For further information: www.cannvasmedtech.com, Media Inquiries: media@cannvasmedtech.com, Investor Relations: ir@cannvasmedtech.com, 1-800-489-0116

Click here to connect with Cannvas MedTech (CSE:MTEC) for an Investor Presentation. 

Source: www.newswire.ca

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less